These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26714815)

  • 21. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.
    Ogata H; Ishikawa Y; Ishikawa Y; Minami R
    J Cardiol; 2009 Feb; 53(1):72-8. PubMed ID: 19167641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Morphometric heart changes and left ventricular function in Duchenne's muscular dystrophy].
    Katlioriene Z
    Medicina (Kaunas); 2003; 39(11):1090-3. PubMed ID: 14646463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function.
    Spinale FG; Holzgrefe HH; Mukherjee R; Hird RB; Walker JD; Arnim-Barker A; Powell JR; Koster WH
    Circulation; 1995 Aug; 92(3):562-78. PubMed ID: 7634471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
    Porcher R; Desguerre I; Amthor H; Chabrol B; Audic F; Rivier F; Isapof A; Tiffreau V; Campana-Salort E; Leturcq F; Tuffery-Giraud S; Ben Yaou R; Annane D; Amédro P; Barnerias C; Bécane HM; Béhin A; Bonnet D; Bassez G; Cossée M; de La Villéon G; Delcourte C; Fayssoil A; Fontaine B; Godart F; Guillaumont S; Jaillette E; Laforêt P; Leonard-Louis S; Lofaso F; Mayer M; Morales RJ; Meune C; Orlikowski D; Ovaert C; Prigent H; Saadi M; Sochala M; Tard C; Vaksmann G; Walther-Louvier U; Eymard B; Stojkovic T; Ravaud P; Duboc D; Wahbi K
    Eur Heart J; 2021 May; 42(20):1976-1984. PubMed ID: 33748842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.
    Silva MC; Magalhães TA; Meira ZM; Rassi CH; Andrade AC; Gutierrez PS; Azevedo CF; Gurgel-Giannetti J; Vainzof M; Zatz M; Kalil-Filho R; Rochitte CE
    JAMA Cardiol; 2017 Feb; 2(2):190-199. PubMed ID: 27926769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cardiac medications on ventricular function in patients with Duchenne muscular dystrophy-related cardiomyopathy.
    Murphy AP; Johnson A; Straub V; Heads-Baister A; Lord S; Bourke JP
    Muscle Nerve; 2021 Aug; 64(2):163-171. PubMed ID: 34050938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy.
    Judge DP; Kass DA; Thompson WR; Wagner KR
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):287-94. PubMed ID: 21812510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy.
    Barp A; Bello L; Politano L; Melacini P; Calore C; Polo A; Vianello S; Sorarù G; Semplicini C; Pantic B; Taglia A; Picillo E; Magri F; Gorni K; Messina S; Vita GL; Vita G; Comi GP; Ermani M; Calvo V; Angelini C; Hoffman EP; Pegoraro E
    PLoS One; 2015; 10(10):e0141240. PubMed ID: 26513582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myocardial strain changes in Duchenne muscular dystrophy without overt cardiomyopathy.
    Ogata H; Nakatani S; Ishikawa Y; Negishi A; Kobayashi M; Ishikawa Y; Minami R
    Int J Cardiol; 2007 Feb; 115(2):190-5. PubMed ID: 16843547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac involvement in Fukuyama muscular dystrophy is less severe than in Duchenne muscular dystrophy.
    Yamamoto T; Taniguchi-Ikeda M; Awano H; Matsumoto M; Lee T; Harada R; Imanishi T; Hayashi N; Sakai Y; Morioka I; Takeshima Y; Iijima K; Saegusa J; Toda T
    Brain Dev; 2017 Nov; 39(10):861-868. PubMed ID: 28578814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of left ventricular dyssynchrony by speckle tracking echocardiography in children with duchenne muscular dystrophy.
    Lanot N; Vincenti M; Abassi H; Bredy C; Agullo A; Gamon L; Mura T; Lavastre K; De La Villeon G; Barrea C; Meyer P; Rivier F; Meli AC; Fauconnier J; Cazorla O; Lacampagne A; Amedro P
    Int J Cardiovasc Imaging; 2022 Jan; 38(1):79-89. PubMed ID: 34905152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies.
    Adorisio R; Mencarelli E; Cantarutti N; Calvieri C; Amato L; Cicenia M; Silvetti M; D'Amico A; Grandinetti M; Drago F; Amodeo A
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33019553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain natriuretic peptide is not predictive of dilated cardiomyopathy in Becker and Duchenne muscular dystrophy patients and carriers.
    Schade van Westrum S; Dekker L; de Haan R; Endert E; Ginjaar I; de Visser M; van der Kooi A
    BMC Neurol; 2013 Jul; 13():88. PubMed ID: 23870371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk Factors for Cerebral Infarction in Duchenne Muscular Dystrophy: Review With our 2 Cases.
    Nozaki F; Kusunoki T; Kumada T; Shibata M; Fujii T
    J Stroke Cerebrovasc Dis; 2019 Sep; 28(9):2453-2458. PubMed ID: 31311695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac atrial pathology in Duchenne muscular dystrophy.
    Greiner E; Breaux A; Kasten J; Seo J; Ollberding NJ; Spar D; Ryan TD; Lang SM; Tian C; Sawnani H; Villa CR
    Muscle Nerve; 2024 May; 69(5):572-579. PubMed ID: 38426616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Blood Pressure and Body Mass Index as Potential Modifiable Factors in The Progression of Myocardial Dysfunction in Duchenne Muscular Dystrophy.
    van de Velde NM; Roest AAW; van Zwet EW; Niks EH
    J Neuromuscul Dis; 2019; 6(1):65-73. PubMed ID: 30400104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac management of ventilator-assisted individuals with Duchenne muscular dystrophy.
    O'Brien L; Varadi R; Goldstein RS; Evans RA
    Chron Respir Dis; 2014 May; 11(2):103-10. PubMed ID: 24728656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance.
    Hor KN; Mazur W; Taylor MD; Al-Khalidi HR; Cripe LH; Jefferies JL; Raman SV; Chung ES; Kinnett KJ; Williams K; Gottliebson WM; Benson DW
    J Cardiovasc Magn Reson; 2011 Oct; 13(1):60. PubMed ID: 22011358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging.
    Batra A; Barnard AM; Lott DJ; Willcocks RJ; Forbes SC; Chakraborty S; Daniels MJ; Arbogast J; Triplett W; Henricson EK; Dayan JG; Schmalfuss C; Sweeney L; Byrne BJ; McDonald CM; Vandenborne K; Walter GA
    BMC Cardiovasc Disord; 2022 Jun; 22(1):260. PubMed ID: 35681116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin receptor-neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime.
    Arcudi A; Di Francesco M; Rodolico D; D'Amario D
    ESC Heart Fail; 2022 Oct; 9(5):3639-3642. PubMed ID: 35712811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.